Australia and New Zealand Anemia in Pregnancy Market Report and Forecast 2024-2032
Australia and New Zealand Anemia in Pregnancy Market Report and Forecast 2024-2032
Australia and New Zealand Anemia in Pregnancy Market Outlook
The Australia and New Zealand anemia in pregnancy market size is anticipated to grow at a CAGR of 8.6% during the forecast period of 2024-2032, driven by the rising incidence of pregnancies across the region.
Anemia in Pregnancy: Introduction
Anemia in pregnancy is a common condition where the mother's blood lacks enough healthy red blood cells to carry adequate oxygen to her body and the fetus. It's often caused by iron deficiency, as the demand for iron and other nutrients increases to support the growing fetus and placenta. Symptoms can include fatigue, weakness, and shortness of breath. Managing anemia is crucial, as severe cases can lead to premature birth and low birth weight.
Key Trends in the Australia and New Zealand Anemia in Pregnancy Market
Enhanced focus on early and regular screening for anemia during prenatal visits to ensure timely diagnosis and intervention.
Rising demand for iron supplements and fortified foods to prevent and treat iron-deficiency anemia among pregnant women.
Growing efforts to educate women about the importance of nutrition and iron-rich diets during pregnancy, emphasizing preventive care.
Development and adoption of advanced, patient-friendly iron supplements and therapies, with a focus on minimizing side effects and improving absorption.
Integration of care between obstetricians, midwives, and nutritionists to provide holistic and individualized care for pregnant women with anemia.
Increased support from global health organizations for programs aimed at reducing anemia in pregnancy, especially in regions with high prevalence rates.
Australia and New Zealand Anemia in Pregnancy Market Segmentation
Market Breakup by Cause
- Folic Acid Deficiency
- Iron Deficiency
- Vitamin B12 Deficiency
- Others
- Iron Products
- Folic Acid Supplementation
- Others
- < 13 Weeks
- 13-27 Weeks
- ≥28 Weeks
- Oral
- Intravenous
- Intramuscular
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
- Hospitals
- Specialty Clinics
- Home Healthcare
- Others
- Australia
- New Zealand
In Australia, the approach to managing anemia in pregnancy is integrated and patient focused. Routine antenatal screening programs to detect and treat anemia early in pregnancy, minimizing complications. Emphasis on public health education regarding nutrition, focusing on diets rich in iron, folate, and other essential nutrients, to prevent anemia. Widespread availability of iron supplements and other nutritional aids provided through healthcare programs. Ongoing research and updated clinical guidelines to optimize the management of anemia in pregnancy, ensuring evidence-based care.
In New Zealand, the focus is on accessible and quality healthcare to address anemia in pregnancy. Universal healthcare system provides accessible antenatal care, including anemia screening and treatment. Healthcare services tailored to meet the diverse cultural needs of the population, ensuring appropriate and effective management of anemia in pregnancy. Integrated care approach involving midwives, GPs, and obstetricians, ensuring consistent and holistic care for pregnant women. Strong health promotion strategies focusing on preventive care, including nutritional education and awareness about anemia during pregnancy.
Australia and New Zealand Anemia in Pregnancy Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.
- Viatris Inc.
- Aspen Pharmacare Australia Pty Ltd
- PharmaCare Laboratories Australia
- AFT Pharmaceuticals
- Bayer AG
- A Nelson & Co Ltd
- BLACKMORES
- Care Pharma
- Amgen Inc.
- Hoffmann-La Roche Ltd.
- AMAG Pharmaceuticals
- Rockwell Medical
- Vifor Pharma Management Ltd.
- Janssen Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Australia and New Zealand Anemia in Pregnancy Market Overview
- 3.1 Australia and New Zealand Anemia in Pregnancy Market Historical Value (2017-2023)
- 3.2 Australia and New Zealand Anemia in Pregnancy Market Forecast Value (2024-2032)
- 4 Australia and New Zealand Anemia in Pregnancy Market Dynamics
- 4.1 Market Drivers and Constraints
- 4.2 SWOT Analysis
- 4.3 Porter’s Five Forces Model
- 4.4 Key Demand Indicators
- 4.5 Key Price Indicators
- 4.6 Industry Events, Initiatives, and Trends
- 4.7 Value Chain Analysis
- 5 Australia and New Zealand Anemia in Pregnancy Market Segmentation
- 5.1 Australia and New Zealand Anemia in Pregnancy Market by Cause
- 5.1.1 Market Overview
- 5.1.2 Folic Acid Deficiency
- 5.1.3 Iron Deficiency
- 5.1.4 Vitamin B12 Deficiency
- 5.1.5 Others
- 5.2 Australia and New Zealand Anemia in Pregnancy Market by Treatment
- 5.2.1 Market Overview
- 5.2.2 Iron Products
- 5.2.3 Folic Acid Supplementation
- 5.2.4 Others
- 5.3 Australia and New Zealand Anemia in Pregnancy Market by Weeks
- 5.3.1 Market Overview
- 5.3.2 < 13 Weeks
- 5.3.3 13-27 Weeks
- 5.3.4 ≥28 Weeks
- 5.4 Australia and New Zealand Anemia in Pregnancy Market by Route of Administration
- 5.4.1 Market Overview
- 5.4.2 Oral
- 5.4.3 Intravenous
- 5.4.4 Intramuscular
- 5.5 Australia and New Zealand Anemia in Pregnancy Market by Distribution Channel
- 5.5.1 Market Overview
- 5.5.2 Hospital Pharmacy
- 5.5.3 Retail Pharmacy
- 5.5.4 Online Pharmacy
- 5.5.5 Others
- 5.6 Australia and New Zealand Anemia in Pregnancy Market by End User
- 5.6.1 Market Overview
- 5.6.2 Hospitals
- 5.6.3 Specialty Clinics
- 5.6.4 Home Healthcare
- 5.6.5 Others
- 5.7 Australia and New Zealand Anemia in Pregnancy Market by Country
- 5.7.1 Market Overview
- 5.7.2 Australia
- 5.7.3 New Zealand
- 6 Patent Analysis
- 6.1 Analysis by Type of Patent
- 6.2 Analysis by Publication year
- 6.3 Analysis by Issuing Authority
- 6.4 Analysis by Patent Age
- 6.5 Analysis by CPC Analysis
- 6.6 Analysis by Patent Valuation
- 6.7 Analysis by Key Players
- 7 Grants Analysis
- 7.1 Analysis by year
- 7.2 Analysis by Amount Awarded
- 7.3 Analysis by Issuing Authority
- 7.4 Analysis by Grant Application
- 7.5 Analysis by Funding Institute
- 7.6 Analysis by NIH Departments
- 7.7 Analysis by Recipient Organization
- 8 Funding Analysis
- 8.1 Analysis by Funding Instances
- 8.2 Analysis by Type of Funding
- 8.3 Analysis by Funding Amount
- 8.4 Analysis by Leading Players
- 8.5 Analysis by Leading Investors
- 8.6 Analysis by Geography
- 9 Partnership and Collaborations Analysis
- 9.1 Analysis by Partnership Instances
- 9.2 Analysis by Type of Partnership
- 9.3 Analysis by Leading Players
- 9.4 Analysis by Geography
- 10 Regulatory Framework
- 10.1 Regulatory Overview
- 11 Supplier Landscape
- 11.1 Viatris Inc.
- 11.1.1 Financial Analysis
- 11.1.2 Product Portfolio
- 11.1.3 Demographic Reach and Achievements
- 11.1.4 Mergers and Acquisitions
- 11.1.5 Certifications
- 11.2 Aspen Pharmacare Australia Pty Ltd
- 11.2.1 Financial Analysis
- 11.2.2 Product Portfolio
- 11.2.3 Demographic Reach and Achievements
- 11.2.4 Mergers and Acquisitions
- 11.2.5 Certifications
- 11.3 PharmaCare Laboratories Australia
- 11.3.1 Financial Analysis
- 11.3.2 Product Portfolio
- 11.3.3 Demographic Reach and Achievements
- 11.3.4 Mergers and Acquisitions
- 11.3.5 Certifications
- 11.4 AFT Pharmaceuticals
- 11.4.1 Financial Analysis
- 11.4.2 Financial Portfolio
- 11.4.3 Demographic Reach and Achievements
- 11.4.4 Mergers and Acquisitions
- 11.4.5 Certifications
- 11.5 Bayer AG
- 11.5.1 Financial Analysis
- 11.5.2 Product Portfolio
- 11.5.3 Demographic Reach and Achievements
- 11.5.4 Mergers and Acquisitions
- 11.5.5 Certifications
- 11.6 A Nelson & Co Ltd
- 11.6.1 Financial Analysis
- 11.6.2 Product Portfolio
- 11.6.3 Demographic Reach and Achievements
- 11.6.4 Mergers and Acquisitions
- 11.6.5 Certifications
- 11.7 BLACKMORES
- 11.7.1 Financial Analysis
- 11.7.2 Product Portfolio
- 11.7.3 Demographic Reach and Achievements
- 11.7.4 Mergers and Acquisitions
- 11.7.5 Certifications
- 11.8 Care Pharma
- 11.8.1 Financial Analysis
- 11.8.2 Product Portfolio
- 11.8.3 Demographic Reach and Achievements
- 11.8.4 Mergers and Acquisitions
- 11.8.5 Certifications
- 11.9 Amgen Inc.
- 11.9.1 Financial Analysis
- 11.9.2 Product Portfolio
- 11.9.3 Demographic Reach and Achievements
- 11.9.4 Mergers and Acquisitions
- 11.9.5 Certifications
- 11.10 Hoffmann-La Roche Ltd.
- 11.10.1 Financial Analysis
- 11.10.2 Product Portfolio
- 11.10.3 Demographic Reach and Achievements
- 11.10.4 Mergers and Acquisitions
- 11.10.5 Certifications
- 11.11 AMAG Pharmaceuticals
- 11.11.1 Financial Analysis
- 11.11.2 Product Portfolio
- 11.11.3 Demographic Reach and Achievements
- 11.11.4 Mergers and Acquisitions
- 11.11.5 Certifications
- 11.12 Rockwell Medical
- 11.12.1 Financial Analysis
- 11.12.2 Product Portfolio
- 11.12.3 Demographic Reach and Achievements
- 11.12.4 Mergers and Acquisitions
- 11.12.5 Certifications
- 11.13 Vifor Pharma Management Ltd.
- 11.13.1 Financial Analysis
- 11.13.2 Product Portfolio
- 11.13.3 Demographic Reach and Achievements
- 11.13.4 Mergers and Acquisitions
- 11.13.5 Certifications
- 11.14 Janssen Pharmaceuticals, Inc.
- 11.14.1 Financial Analysis
- 11.14.2 Product Portfolio
- 11.14.3 Demographic Reach and Achievements
- 11.14.4 Mergers and Acquisitions
- 11.14.5 Certifications
- 11.15 Teva Pharmaceutical Industries Ltd.
- 11.15.1 Financial Analysis
- 11.15.2 Product Portfolio
- 11.15.3 Demographic Reach and Achievements
- 11.15.4 Mergers and Acquisitions
- 11.15.5 Certifications
- 12 Australia and New Zealand Anemia in Pregnancy Market - Distribution Model (Additional Insight)
- 12.1 Overview
- 12.2 Potential Distributors
- 12.3 Key Parameters for Distribution Partner Assessment
- 13 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 14 Company Competitiveness Analysis (Additional Insight)
- 14.1 Very Small Companies
- 14.2 Small Companies
- 14.3 Mid-Sized Companies
- 14.4 Large Companies
- 14.5 Very Large Companies
- 15 Payment Methods (Additional Insight)
- *Additional insights provided are customisable as per client requirements.
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook